---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-253506"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-06-02T20:10:13+00:00"
generated_at: "2026-06-02T20:15:38.022123+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8

## Summary
- Issued 31,958 and 32,710 common shares to Streeterville on May 26 and June 1, 2026, respectively, in exchange for 3.72 and 4.2 Series Q Preferred shares.
- Shares issued under Section 3(a)(9) exemption; no cash consideration exchanged.
- Annual meeting reconvened June 2 but further adjourned to June 8 for stockholders to review proxy supplement filed May 29.
- Record date remains April 15; stockholders who already voted need not take further action.

## SEC filing metadata
- accession: 0001193125-26-253506
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-06-02T20:10:13+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/0001193125-26-253506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/d95782d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-253506
- JSON: https://secwatch.observer/filing/0001193125-26-253506.json
- Plain text: https://secwatch.observer/filing/0001193125-26-253506.txt

## Source-grounded claims
- claim_id: 3fdf4c14e0fd857a4b52734e08e3043aaecb1214
  claim: Jaguar Health, Inc. entered into First Exchange Agreement with Streeterville Capital, LLC (effective 2026-05-26).
  evidence_excerpt: On May 26, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “First Exchange Agreement”), pursuant to which the Company issued 31,958 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”) to Streeterville in exchange for an aggregate of 3.72 outstanding shares of Series Q Preferred Stock held by Streeterville (the “First Exchanged Preferred Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/0001193125-26-253506-index.htm
- claim_id: 66c454947ef8452685b80833ef937efbdd8e03e9
  claim: Jaguar Health, Inc. entered into Second Exchange Agreement with Streeterville Capital, LLC (effective 2026-06-01).
  evidence_excerpt: On June 1, 2026, the Company entered into another privately negotiated exchange agreement with Streeterville (the “Second Exchange Agreement”), pursuant to which the Company issued 32,710 shares (the “Second Exchange Shares”) of Common Stock to Streeterville in exchange for an aggregate of 4.2 outstanding shares of Series Q Preferred Stock held by Streeterville (the “Second Exchanged Preferred Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/0001193125-26-253506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.